Health economics of care for patients with cancer and intractable disease in Japan.
Concern about the economic aspect of cancer care is increasing. However, economic evaluations for cancer care are deficient in a number of areas, despite recent important contributions. To generate better evidence for economic evaluation of care for patients with cancer and intractable disease, the recent trends and problems with economic evaluations in these areas in Japan are examined. Several examples of economic evaluations, such as those concerned with bone marrow transplantation for leukemias, breast-conserving treatment for early breast cancer, and antiemetic treatment for patients receiving cancer chemotherapy, showed substantial possibilities for evaluating value for money in health care with a view to establishing an effective and efficient health care system.
Hisashige
A
A
Department of Preventive Medicine, University of Tokushima, School of Medicine, Japan.
Katayama
T
T
Mikasa
H
H
D003362:Cost-Benefit Analysis; D003695:Delivery of Health Care / Q000191:economics*; D019468:Disease Management; D017048:Health Care Costs / Q000706:statistics & numerical data; D006801:Humans; D007564:Japan; D009369:Neoplasms / Q000191:economics* / Q000628:therapy*; D013673:Technology Assessment, Biomedical